Brazil pulpmaker Suzano agrees to buy two Pactiv plants in US for $110 mln-August 2024-www.financetom.com

Brazil pulpmaker Suzano agrees to buy two Pactiv plants in US for $110 mln

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Brazil pulpmaker Suzano agrees to buy two Pactiv plants in US for $110 mln

Jul 12, 2024 2:33 PM

SAO PAULO, July 12 (Reuters) - Brazilian pulpmaker

Suzano has reached an agreement to buy two paper

plants from Pactiv Evergreen ( PTVE ) in the United States for

$110 million, the companies announced in filings on Friday.

Previous page： Invesco, CI Global Asset Management Complete Deal for Canadian Fund Business Next page： Perpetua Resources Advances Stibnite Project in Idaho After Favorable Court Ruling

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Invesco, CI Global Asset Management Complete Deal for Canadian Fund Business

Jun 1, 2026

08:25 AM EDT, 06/01/2026 (MT Newswires) -- Invesco ( IVZ ) and CI Global Asset Management said Monday they have completed the transfer of management agreements for Invesco's ( IVZ ) Canadian fund business, covering about 27 billion Canadian dollars ($19.52 billion) in assets under management. The companies also said they formed a long-term partnership under which Invesco ( IVZ...

Perpetua Resources Advances Stibnite Project in Idaho After Favorable Court Ruling

Jun 1, 2026

08:28 AM EDT, 06/01/2026 (MT Newswires) -- Perpetua Resources ( PPTA ) continues to advance the Stibnite gold-antimony project in Idaho following a court decision denying a request to block development, the company said Monday. The U.S. District Court of Idaho denied on Friday a motion for a preliminary injunction filed by special interest groups in 2025. The court found...

GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint

Jun 1, 2026

08:26 AM EDT, 06/01/2026 (MT Newswires) -- GRAIL's (GRAL) stock fell 11% in Monday's premarket session after the company said over the weekend that the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint. The NHS-Galleri trial evaluated a primary endpoint of Stage III and IV diagnoses in a group of 12 cancers. The company said...

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Jun 1, 2026

— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity — — Upfront Proceeds Expected to Fully Fund EDG-7500 Development Through Potential Approval — — On Track to Report 12-Week CIRRUS-HCM Part D Data in Q2 2026...